Phase 2 Psilocybin Therapy Trial for Patients With Treatment-Resistant…
cannabis company Creso Pharma COPHF‘s wholly owned Psychedelics subsidiary Halucenex Life Sciences Inc. shared promising early insights into its progress Phase 2 clinical study Evaluating